141
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The Mutational Landscape of Adenoid Cystic Carcinoma

      research-article
      1 , 2 , 1 , 1 , 1 , 2 , 1 , 2 , 3 , 1 , 1 , 1 , 1 , 3 , 1 , 1 , 1 , 1 , 4 , 5 , 6 , 6 , 2 , 7 , 8 , 9 , 10 , 11 , 12 , 1 , 12 , 1 , 12 ,   1 , 1 ,   13 , 10 , 11 , 2 , 13 , 13 , 1 , 14 , *
      Nature genetics

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Adenoid cystic carcinomas (ACCs) are among the most enigmatic of human malignancies. These aggressive salivary cancers frequently recur and metastasize despite definitive treatment, with no known effective chemotherapy regimen. Here, we determined the ACC mutational landscape and report the exome or whole genome sequences of 60 ACC tumor/normal pairs. These analyses revealed a low exonic somatic mutation rate (0.31 non-silent events/megabase) and wide mutational diversity. Interestingly, mutations selectively involved chromatin state regulators, such as SMARCA2, CREBBP, and KDM6A, suggesting aberrant epigenetic regulation in ACC oncogenesis. Mutations in genes central to DNA damage and protein kinase A signaling also implicate these processes. We observed MYB-NFIB translocations and somatic mutations in MYB-associated genes, solidifying these aberrations as critical events. Lastly, we identified recurrent mutations in the FGF/IGF/PI3K pathway that may potentially offer new avenues for therapy (30%). Collectively, our observations establish a molecular foundation for understanding and exploring new treatments for ACC.

          Related collections

          Most cited references55

          • Record: found
          • Abstract: found
          • Article: not found

          Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.

          The cBioPortal for Cancer Genomics (http://cbioportal.org) provides a Web resource for exploring, visualizing, and analyzing multidimensional cancer genomics data. The portal reduces molecular profiling data from cancer tissues and cell lines into readily understandable genetic, epigenetic, gene expression, and proteomic events. The query interface combined with customized data storage enables researchers to interactively explore genetic alterations across samples, genes, and pathways and, when available in the underlying data, to link these to clinical outcomes. The portal provides graphical summaries of gene-level data from multiple platforms, network visualization and analysis, survival analysis, patient-centric queries, and software programmatic access. The intuitive Web interface of the portal makes complex cancer genomics profiles accessible to researchers and clinicians without requiring bioinformatics expertise, thus facilitating biological discoveries. Here, we provide a practical guide to the analysis and visualization features of the cBioPortal for Cancer Genomics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

            Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens. In a phase III, international, multicentre, controlled, parallel-group, open-label trial, patients with higher-risk myelodysplastic syndromes were randomly assigned one-to-one to receive azacitidine (75 mg/m(2) per day for 7 days every 28 days) or conventional care (best supportive care, low-dose cytarabine, or intensive chemotherapy as selected by investigators before randomisation). Patients were stratified by French-American-British and international prognostic scoring system classifications; randomisation was done with a block size of four. The primary endpoint was overall survival. Efficacy analyses were by intention to treat for all patients assigned to receive treatment. This study is registered with ClinicalTrials.gov, number NCT00071799. Between Feb 13, 2004, and Aug 7, 2006, 358 patients were randomly assigned to receive azacitidine (n=179) or conventional care regimens (n=179). Four patients in the azacitidine and 14 in the conventional care groups received no study drugs but were included in the intention-to-treat efficacy analysis. After a median follow-up of 21.1 months (IQR 15.1-26.9), median overall survival was 24.5 months (9.9-not reached) for the azacitidine group versus 15.0 months (5.6-24.1) for the conventional care group (hazard ratio 0.58; 95% CI 0.43-0.77; stratified log-rank p=0.0001). At last follow-up, 82 patients in the azacitidine group had died compared with 113 in the conventional care group. At 2 years, on the basis of Kaplan-Meier estimates, 50.8% (95% CI 42.1-58.8) of patients in the azacitidine group were alive compared with 26.2% (18.7-34.3) in the conventional care group (p<0.0001). Peripheral cytopenias were the most common grade 3-4 adverse events for all treatments. Treatment with azacitidine increases overall survival in patients with higher-risk myelodysplastic syndromes relative to conventional care.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1.

              Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide. To explore the genetic origins of this cancer, we used whole-exome sequencing and gene copy number analyses to study 32 primary tumors. Tumors from patients with a history of tobacco use had more mutations than did tumors from patients who did not use tobacco, and tumors that were negative for human papillomavirus (HPV) had more mutations than did HPV-positive tumors. Six of the genes that were mutated in multiple tumors were assessed in up to 88 additional HNSCCs. In addition to previously described mutations in TP53, CDKN2A, PIK3CA, and HRAS, we identified mutations in FBXW7 and NOTCH1. Nearly 40% of the 28 mutations identified in NOTCH1 were predicted to truncate the gene product, suggesting that NOTCH1 may function as a tumor suppressor gene rather than an oncogene in this tumor type.
                Bookmark

                Author and article information

                Journal
                9216904
                2419
                Nat Genet
                Nat. Genet.
                Nature genetics
                1061-4036
                1546-1718
                12 June 2013
                19 May 2013
                19 May 2013
                19 November 2013
                : 45
                : 7
                : 791-798
                Affiliations
                [1 ]Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [2 ]Head and Neck Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [3 ]Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [4 ]Genomics Core, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [5 ]Pathology Core, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [6 ]Molecular Cytogenetics Core, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [7 ]Department of Surgical Oncology, National Cancer Center Singapore, Singapore.
                [8 ]Department of Otolaryngology-Head and Neck Surgery, VU University Medical Center, Amsterdam, Netherlands.
                [9 ]Department of Oral and Maxillofacial Surgery and Oral Pathology, VU University Medical Center, Academic Centre for Dentistry, Amsterdam, Netherlands.
                [10 ]Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
                [11 ]Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA.
                [12 ]Department of Computer Science and Center for Computational Molecular Biology, Brown University, Rhode Island, RI.
                [13 ]Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY.
                [14 ]Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.
                Author notes
                [* ]Correspondence and requests for materials should be addressed to T.A.C. ( chant@ 123456mskcc.org )
                [†]

                These authors contributed equally to this work.

                Article
                NIHMS474972
                10.1038/ng.2643
                3708595
                23685749
                53c9383d-cd17-4893-8ed7-0ccee32e26cf

                Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Funding
                Funded by: National Cancer Institute : NCI
                Award ID: R01 CA154767 || CA
                Categories
                Article

                Genetics
                Genetics

                Comments

                Comment on this article